
Type 2 Diabetes
Latest News
Latest Videos

Shorts






More News

The integrated CGM, first cleared over-the-counter for adults in 2024, is now available without a prescription for people 2 years of age and older who do not use insulin.

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

This decision marks the first FDA-approved inhaled insulin for pediatric patients.

FDA approved insulin glargine-aldy as an interchangeable biosimilar to Lantus for type 1 diabetes and adult type 2 diabetes.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A new review highlights how rising childhood obesity, genetic susceptibility, and early-life gut microbiota changes contribute to youth-onset type 2 diabetes.









